{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-307303","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2022-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.621382+00:00","generated_at":"2026-06-21T03:22:44.335672+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Quince Therapeutics receives Nasdaq bid price deficiency notice; 180-day cure period.","bullets":["Notice on Dec 13, 2022: closing bid price below $1.00 for 30 consecutive days.","Initial compliance period until June 12, 2023 to regain bid price ≥$1.00 for 10 days.","If not compliant by June 12, may transfer to Nasdaq Capital Market for second 180-day period.","Failure to cure could result in delisting from Nasdaq Global Select Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-307303","json":"https://secwatch.observer/filing/0001193125-22-307303.json","markdown":"https://secwatch.observer/filing/0001193125-22-307303.md","text":"https://secwatch.observer/filing/0001193125-22-307303.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312522307303/0001193125-22-307303-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312522307303/d433742d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T03:22:44.335672+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3ae63231b1fffcf40506b5d1f3cf3dfd3d73b991","claim":"Quince Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).","evidence_excerpt":"December 13, 2022, Quince Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based on the closing bid price of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for the last 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Select Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312522307303/0001193125-22-307303-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}